JP2006506942A - アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法 - Google Patents
アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法 Download PDFInfo
- Publication number
- JP2006506942A JP2006506942A JP2003563456A JP2003563456A JP2006506942A JP 2006506942 A JP2006506942 A JP 2006506942A JP 2003563456 A JP2003563456 A JP 2003563456A JP 2003563456 A JP2003563456 A JP 2003563456A JP 2006506942 A JP2006506942 A JP 2006506942A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- amino acid
- pharmaceutical composition
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(CCC(*)=C)C(*C(CC1C=CC=CC1)C(C1(C)*C1)=O)=O Chemical compound CC(CCC(*)=C)C(*C(CC1C=CC=CC1)C(C1(C)*C1)=O)=O 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35257802P | 2002-01-31 | 2002-01-31 | |
US39226602P | 2002-07-01 | 2002-07-01 | |
US10/235,852 US20040052928A1 (en) | 2002-09-06 | 2002-09-06 | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US43645302P | 2002-12-27 | 2002-12-27 | |
PCT/IL2003/000079 WO2003063760A2 (fr) | 2002-01-31 | 2003-01-30 | Peptides, anticorps diriges contre les maladies associees a l'amyloide et procedes utilisant ces peptides et ces anticorps en vue de diagnostiquer et de traiter ces maladies |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006506942A true JP2006506942A (ja) | 2006-03-02 |
JP2006506942A5 JP2006506942A5 (fr) | 2006-04-13 |
Family
ID=27671045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003563456A Pending JP2006506942A (ja) | 2002-01-31 | 2003-01-30 | アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1534310A4 (fr) |
JP (1) | JP2006506942A (fr) |
KR (1) | KR20040081165A (fr) |
AU (1) | AU2003207973A1 (fr) |
CA (1) | CA2473987C (fr) |
WO (1) | WO2003063760A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007537699A (ja) * | 2003-06-30 | 2007-12-27 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. | アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040052928A1 (en) | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US7781396B2 (en) | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
DE602004020179D1 (de) | 2003-01-07 | 2009-05-07 | Univ Ramot | Peptidenanostrukturen die fremdmaterial enthalten, und verfahren zur herstellung derselben |
WO2006013552A2 (fr) | 2004-08-02 | 2006-02-09 | Ramot At Tel Aviv University Ltd. | Articles de nanostructures a base de peptides et leur procede de formation |
EP1973928A2 (fr) | 2005-10-11 | 2008-10-01 | Ramot at Tel-Aviv University Ltd. | Hydrogels auto-assembles a base de fmoc-ff |
US8101578B2 (en) | 2006-04-28 | 2012-01-24 | Kagoshima University | Amyloid [β] Beta fibrillogenesis-inhibiting peptide |
CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
EP2142514B1 (fr) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase |
SG178953A1 (en) | 2009-09-11 | 2012-04-27 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
ES2586231T3 (es) | 2010-03-03 | 2016-10-13 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (fr) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Nouveaux inhibiteurs |
CA2814905A1 (fr) * | 2010-10-29 | 2012-05-03 | Merz Pharma Gmbh & Co. Kgaa | Derives d'indole et procede pour leur preparation |
EP2640737B1 (fr) | 2010-11-15 | 2018-08-29 | Ramot at Tel-Aviv University Ltd. | Analogues dipeptidiques pour le traitement d'états pathologiques associé à la formation de fibrilles amyloïdes |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
WO2014041069A1 (fr) | 2012-09-12 | 2014-03-20 | Neurimmune Holding Ag | Anticorps spécifiques du polypeptide amyloïde des îlots humains (hiapp) et leurs utilisations |
KR101956302B1 (ko) * | 2016-11-30 | 2019-03-11 | 연세대학교 산학협력단 | 세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물 |
CA3072884A1 (fr) | 2017-08-11 | 2019-02-14 | University Of Kentucky Research Foundation | Compose therapeutique anti-neurodenerescence, procede de fabrication et utilisation |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
TW202144387A (zh) * | 2020-02-11 | 2021-12-01 | 美商聯合生物醫學公司 | 針對胰島澱粉樣多肽(iapp)的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑 |
WO2024121156A1 (fr) * | 2022-12-05 | 2024-06-13 | Neurimmune Ag | Composés cycliques et leur utilisation dans des dosages pour détecter des anticorps |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6344895A (ja) * | 1986-08-13 | 1988-02-25 | Kyowa Hakko Kogyo Co Ltd | 抗アミロイドa蛋白質単クロ−ン性抗体 |
DE69408145T2 (de) * | 1993-07-19 | 1998-09-03 | Resolution Pharm Inc | Hydrazine mit einer n3s konfiguration als radionukleide chelatoren |
US6303567B1 (en) * | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
EP0941334B1 (fr) * | 1996-11-06 | 2004-06-02 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Proproteines similaires a l'exotoxine de pseudomonas, pouvant etre activees par une protease |
JP2000193661A (ja) * | 1998-12-25 | 2000-07-14 | Tokyo Rika Kikai Kk | 痴呆症の検査方法 |
-
2003
- 2003-01-30 CA CA2473987A patent/CA2473987C/fr not_active Expired - Fee Related
- 2003-01-30 WO PCT/IL2003/000079 patent/WO2003063760A2/fr active Search and Examination
- 2003-01-30 EP EP03704977A patent/EP1534310A4/fr not_active Withdrawn
- 2003-01-30 KR KR10-2004-7011868A patent/KR20040081165A/ko not_active Application Discontinuation
- 2003-01-30 JP JP2003563456A patent/JP2006506942A/ja active Pending
- 2003-01-30 AU AU2003207973A patent/AU2003207973A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007537699A (ja) * | 2003-06-30 | 2007-12-27 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. | アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2003063760A2 (fr) | 2003-08-07 |
AU2003207973A1 (en) | 2003-09-02 |
EP1534310A4 (fr) | 2006-05-31 |
EP1534310A2 (fr) | 2005-06-01 |
WO2003063760A3 (fr) | 2005-02-10 |
CA2473987C (fr) | 2013-11-19 |
CA2473987A1 (fr) | 2003-08-07 |
KR20040081165A (ko) | 2004-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5137400B2 (ja) | アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法 | |
JP2006506942A (ja) | アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法 | |
US8012929B2 (en) | Peptides directed for diagnosis and treatment of amyloid-associated diseases | |
EP0843516B1 (fr) | Peptides et compositions pharmaceutiques a base de tels peptides, destinees au traitement de troubles ou d'affections associees a un pliage anormal de proteine dans des depots amyloides ou de type amyloide | |
EP0584452B1 (fr) | Nouveaux précurseurs de protéines amyloides et méthodes les utilisant | |
US20050020809A1 (en) | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | |
US20030013648A1 (en) | Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders | |
HUE028729T2 (en) | Compositions for the prevention and treatment of neurodegenerative diseases | |
AU2004203461B2 (en) | Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases | |
US8003612B2 (en) | Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein disorders | |
IL210418A (en) | Peptides for treating amyloid-associated diseases | |
IL172788A (en) | Use of peptides in the manufacture of medicaments for treating amyloid-associated diseases | |
AU2009227824A1 (en) | Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof | |
US7276483B1 (en) | Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051202 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080711 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080922 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080930 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081111 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081118 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081126 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090811 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091110 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091204 |